How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
DUBLIN, Calif., Nov. 17 /PRNewswire/ -- Carl Zeiss Meditec, Inc., a leaderin ophthalmic devices and systems, today announced the VISUCAM PRO NMnon-mydriatic fundus camera for retinal imaging was granted 510(k) clearanceby the U.S. Food and Drug Administration.
Building on Zeiss' reputation for quality optics and innovation,VISUCAM PRO NM enables practitioners to capture high-resolution, digitalimages of the retina and posterior segment of the eye through the smallestpupil size in the industry (3.3 millimeters compared to the competitors'3.7 millimeters). This eliminates the need to dilate the pupil prior totesting.
Additionally, the technology captures high-resolution images at 30- and45- degree field angles allowing for early documentation of such conditions asdiabetic retinopathy, age-related macular degeneration (AMD) and glaucoma.
"Zeiss' goal is to provide products that benefit clinicians and patientsby improving outcomes, reducing costs and improving the quality of carethroughout the ophthalmology industry," said Jim Taylor, president and chiefexecutive officer of Carl Zeiss Meditec, Inc. "The VISUCAM PRO NMaccomplishes this goal by providing the most advanced fundus imaging availablein the industry to document retinal pathology."
Unlike other non-mydriatic fundus cameras on the market, VISUCAM PRO NM isan all-in-one unit without the need for external wires or peripheral cameras.The unit includes a 17-inch flat panel monitor, which can be easily rotatedfor patient education. The industrial-grade internal digital sensor requiresno maintenance, keeping the optical path free of dust or other artifacts.